INTRODUCTION
The Food and Drug Administration (FDA) recently released a report titled "Innovation or Stagnation: Challenges and Opportunities on the Critical Path to New Medical Products." This report focused on the current deceleration of innovative and pioneering medical therapies capable of reaching the patients who might benefit, 1 and states that:
For many therapeutics, effectiveness criteria are best defined by the practitioners and patients who use the products. Much work needs to be done on clinical trial design and patient-driven outcome measures to ensure that endpoints in new therapeutic areas accurately reflect patient needs and values. Community (health professional and patient) consensus on appropriate outcome measures and therapeutic claims can lay a clear development path for new therapeutics, especially when there is international regulatory harmonization. (p. 24)
Although a sound understanding of the biomechanisms of potentially beneficial medical therapies will always be of great importance, most medical treatments aim to improve patients' symptoms and/or functioning and their effects on healthrelated quality of life (HRQoL). Whereas it is generally recognized that patient-reported outcomes are relevant, there is no consensus regarding which HRQoL outcome measures are appropriate to assess HRQoL and how much change on those measures depicts significant improvement in HRQoL. The clinically important difference (CID) reflects the amount of change (either improvement or decline) in HRQoL that is meaningful to patients and/or their health care providers. Although some researchers and practitioners will argue that only the patient's perspective 2 should inform what constitutes a meaningful change, it is clear that the FDA has determined that decisions on which measures to use and what CID thresholds constitute small, moderate, and large changes in HRQoL should reflect both health professionals and patients' needs and values. 1 In 1989 Jaeschke et al. 3 described a minimal clinically important difference (MCID) in HRQoL as "the smallest difference in a score of a domain of interest that patients perceive to be beneficial and that would mandate, in the absence of troublesome side effects and excessive costs, a change in the patient's management." We view CIDs as an expansion of the 1989 term because the CIDs recognize that within a disease condition, unique treatment options can have different risks. Therefore, a patient and clinician may seek a moderate or large CID in HRQoL if the investment and/or risk of a treatment is greater than minimal. Hence, CIDs examine the amount of change associated with a small, moderate, and large improvement or decline in HRQoL. Another popular term for interpreting the magnitude of HRQoL change scores is minimal important difference, and is generally linked to the smallest change in HRQoL that is important to patients. 2 With the support of the Agency for Healthcare Research and Quality, we conducted a 4-year clinical investigation to develop criteria for assessing HRQoL in patients with chronic obstructive pulmonary disease (COPD) that could be used to evaluate therapies. Treatment goals for COPD patients focus on enhancing functioning, relieving dyspnea and other symptoms, improving emotional difficulties, and mastering situations that may irritate this condition. 4 Therefore, we determined CID thresholds for both a well-known disease-specific HRQoL instrument, the Chronic Respiratory Disease Questionnaire (CRQ) 5 and the most widely used generic measure of HRQoL, the Medical Outcomes Study Short Form 36-item survey (SF-36, version 2.0). 6 We selected these two instruments for specific reasons. The CRQ was developed in 1987 by Guyatt et al. 5 to measure the 4 important HRQoL domains associated with COPD: dyspnea, fatigue, emotional functioning, and mastery (feelings of control over of the disease). The items for each of these domains use a 7-point scale, and there are 5, 4, 7, and 4 items for the respective domains. Hence, scores range from 5 to 35 in the dyspnea domain, 4 to 28 in the fatigue, 7 to 49 in emotional functioning, and 4 to 28 in mastery. A unique feature of the dyspnea domain is that each patient identifies 5 activities that are affected by Figure 1 . Expert panel selection, Delphi, and consensus process.
her/his shortness of breath, and then rates their limitations on each of these patient-specific activities across the time of their enrollment. We chose the CRQ instrument because of (1) the repeated demonstration of its validity among patients with chronic airflow difficulties; 7, 8 and (2) its documented acceptability among these patients in longitudinal studies, which is likely attributable to these 5 activities that each patient selects. 8, 9 Similarly, we had 3 reasons for selecting version 2.0 of the SF-36, which has eight scales, each having a 0-100 scoring range: physical functioning, roles affected by physical health, bodily pain, general health, vitality, social functioning, roles affected my emotional health, and mental health. First, the SF-36 is the most widely used HRQoL measure in the world. 10 Second, version 2.0 provides greater item comprehension and improved measurement. 6 And third, use of this generic instrument provides the potential for comparability of CIDs across different diseases or conditions.
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Our goal was to report and explicate the triangulated results from evidence-based explorations to identify thresholds for the MCID for HRQoL measures and for moderate and large CIDs. Our triangulation investigation examined the perspectives of three different groups with a stake in the management: a 9-member expert panel of North American physicians familiar with both the treatment of COPD patients and the measurement of generic and COPD-specific HRQoL; outpatients with COPD attending 2 Midwestern primary care clinics who participated in bimonthly HRQoL evaluations over 1 year; and the primary care physicians (PCPs) of these outpatients as they followed their patients clinically over time.
Although several methods were previously proposed for this purpose on interpreting HRQoL change in scores among patient with COPD, none have adequately incorporated clinicians' insight. Indeed, the seminal MCID investigation of Jaeschke et al. reported on the use of a clinical consensus panel to formulate hypothesized values of the MCID for the dyspnea, fatigue, and emotional function domains of the Chronic Heart Disease Questionnaire (CHQ) and the CRQ. 3 However, the only credential for panel membership was that panelists had "extensive experience with their [CHQ and CRQ] administration." (p. 409) Therefore, our study was designed to improve on that process by assembling an expert panel of physicians who treat patients with COPD and are accomplished in their research on these patients' HRQoL. 12 Moreover, the subsequent anchor-based MCID derivations in the Jaeschke et al. 3 study did not ask the attending physician if he/she concurred with the patient's assessment of HRQoL change. To move toward a community consensus, our triangulation study collected both patient-reported changes and evaluations of clinically significant change by the patients' PCPs. Furthermore, we wanted to explore what changes in care were associated with clinician-identified changes. In addition, Jaeschke and colleagues averaged the absolute values of change scores from patients declaring a minimal improvement or decline in HRQoL to find the MCID. However, a more recent research by Cella et al. 13 reported that these HRQoL changes are not symmetrical, and patients who reported getting worse had generally larger change scores than those with similar improvements. As a result, we hoped to improve on prior CRQ MCID studies by considering small, moderate, and large improvements in separate analyses from small, moderate, and large declines. Finally, with the exception of expert panel reports, 12, 14 no known published studies have directly investigated CID anchors and change scores for individuals on the SF-36 in this disease group. 15 Therefore, our current study report is the first known investigation that directly incorporates patients and clinicians' perceptions of important change to the SF-36 scales among patients with COPD.
METHODS

Expert Panel Processes
Figure 1 depicts our procedures for selecting and facilitating the Delphi and consensus panel processes: a more detailed description can be found elsewhere. 12 In addition to working toward consensus on the CID levels that represent small, moderate, and large improvements and declines on the CRQ and SF-36 measures, this expert panel also successfully reached agreement on the criteria for selection of appropriate outpatients with COPD for our prospective study and advised us on the best content wordings for items used to elicit these outpatients' global assessments of change on each CRQ and SF-36 domain.
Chronic Obstructive Pulmonary Disease Outpatients
Details of patient enrollment and participation are outlined in Figure 2 . First, the expert panel-derived criteria for potential enrollment were applied to data in the electronic medical records systems at Wishard Health Services in Indianapolis and the St. Louis Veteran Affairs Medical Center. These criteria are listed in the first box of Figure 2 . The generality of these potentially eligible criteria led to many patients being initially selected (n=3,128). This electronic search cast the widest administrative net for potential cases. When these patients' PCPs reviewed these selected charts to confirm the potential COPD diagnoses in their individual patients, far fewer COPD cases (n=1,795) were identified. The patients thus identified were interviewed for eligibility and interest in this study at their next scheduled clinic visit, but many either refused to participate or were deemed ineligible because they did not know they had lung disease, did not have a phone in their home, or could not hear well enough to use the telephone. Interested and eligible participants signed informed consents. Next, they provided enrollment data by answering several Outcomes Study social support scale, 18 Mirowsky and Ross' sense of control measure, 19 the 2-summary religiosity and spirituality items from the Fetzner instrument, 20 educational attainment, employment status, perceived income adequacy, and income. To assist our participants with recall at future telephone interviews, we employed the use of memory markers at the end of each interview that allowed participants to record a significant or memorable aspect about their day ("I had lunch with my sister Frances today"). This memory marker was then read back to the participant at their next interview to assist with the recall. Subsequently, Louis Harris and Associates conducted followup telephone interviews every 2 months for a 1-year period during which they readministered the CRQ and the SF-36, as well as global assessments of change for each relevant dimension. However, if during the year an outpatient visited the PCP at least 1 month-but not more than 2 months-after a telephone interview, this triggered an early follow-up telephone interview within 72 hours after the PCP office visit. These visit-triggered interviews were intended to capture the HRQoL of some outpatients at a juncture when PCP assessments of disease-related changes could also be obtained. Moreover, we hoped that many of these early follow-up interviews would reflect extreme fluctuations in HRQoL because of exacerbations that prompted such PCP visits.
Primary Care Physicians
Forty-three PCPs at the Indianapolis 29 and the St. Louis 14 sites volunteered to participate in this study as depicted in Figure 3 . By confirming disease eligibility; completing baseline evaluations of disease severity; estimating the potential for hospitalization and mortality; and indicating referrals, tests, and medication use, these PCPs provided necessary and direct input from health care professionals both before and during patient enrollments. If a patient participant returned for a PCP office visit during the participant's year of enrollment, the PCP also assessed disease-related change over time so that PCP-rated change could be directly compared (linked) to the patients' reports of change in their HRQoL. If the PCP rated a participant to have a clinically significant change in their COPD, the PCP was also prompted to evaluate the change as an improvement or a decline; the magnitude of that change (small, moderate, or large); and whether the change resulted in a medication change, ordering laboratory test or procedures, or a referral to a specialist. We provided no specific definitions for the change assessments (no change; or small, moderate,orlargeimprovementordecline),andeachparty(patient andPCP)wasblinded totheother's assessment.
Statistical Procedures
We calculated each CRQ domain or SF-36 scale change scores (time 2-time 1, where time 2=current follow up assessment and time 1=immediately previous bimonthly assessment) for each adjacent pair of completed interviews. The domain or scale change scores were then categorized based on the patient's transition rating index (TRI) for the dimension using the global assessments of change in HRQoL that were included in each follow-up interview. A complete list of the global assessment items used for each of the 4 CRQ domains and 8 SF-36 scales are provided in Figure 4 . If the participant responded that he/she was better, we then asked him/her to describe by how much better using a TRI of 1 (almost the same, hardly any better) to 7 (a very great deal better). Likewise, if the participant was worse, he/she provided a −1 (almost the same, hardly any worse) to −7 (a very great deal worse) TRI. The TRI equaled 0 for those participants who reported being "about the same." The TRIs were classified using the traditional approach described by Juniper et al. 21 and endorsed by Jaeschke et al. (Fig. 5) .
Once classified into the appropriate change categories, we determined the optimal thresholds for no change, and small, moderate, and large improvements and declines for each HRQoL measure by averaging all of the change scores within a patient-perceived TRI classification. 3 We used the PCP's blinded assessment of change in the patient's COPD because the last linked clinical encounter in the same manner to classify linked patient change scores in all HRQoL measures before averaging (Fig. 3) . All analyses were conducted using SPSS, version 12.0. 
RESULTS
After consideration of the panel's premeeting Delphi activities, each member of this expert panel was asked to articulate their personal understandings of a clinically important change on each CRQ domain and SF-36 scale at the face-to-face consensus meeting. Panelists then agreed to calculate a unit of measurement for each domain and scale named a state change, which is equivalent to the amount of change in the total score on most domain or scale items that results in moving up just one response choice. Using the state change metric, this North American physician expert panel reached consensus on the CIDs for small, moderate, and large improvements and declines (Table 1) . State changes for the CRQ dimensions were always 1 unit in magnitude, but the SF-36 state changes varied from 5 to 12.5 units on the 0-100 scales. The expert panel recommended that small CID thresholds were at least 2 state changes for all CRQ dimensions, and at least 1 state change for each SF-36 scale. Although the panel process was quite insightful, it is important to note that our investigation had a priori designated the expert panel CIDs, which would be the least important of the three perspectives sampled in this study.
12 Table 2 presents the characteristics of our COPD outpatient sample at baseline. These data reflect the considerable socioeconomic burdens this population faced, with one quarter being self-identified minorities, over half never having completed high school, and two thirds reporting annual incomes below $20,000. In addition, nearly all COPD enrollees had fair or poor self-rated health, were either unable to work or had retired, and had a smoking history of more than 20 pack years. Of the 610 outpatients who completed baseline interviews, 554 (91%) completed their first follow-up interview 2 months later. The 4-, 6-, 8-, 10-, and 12-month completion rates were 522 (86%), 504 (83%), 484 (79%), 462 (76%), and 462 (76%), respectively, and demonstrated excellent cooperation from this generally disadvantaged patient sample.
During the 2,988 follow-up interviews, most participants (59-74%) reported no change or being about the same compared to their prior interview when asked to make a global assessment of change for each CRQ dimension and SF-36 scale (left-hand columns of Table 3 ). Of these 2,988 follow-up interviews, 410 were linked to PCP office visits. Therefore, we had both the patient's assessment of change and the PCP's assessment of change in the patient's COPD for these linked interviews, which occurred mostly within 24 hours of the visit with a maximum allowance of 72 hours between the visit and the follow-up patient interview. Most PCPs (80%) reported no change in the patient's condition. As a result, there are few or no patient/PCP-linked encounters identifying either improve- The panel reached consensus that, in the absence of evidence to the contrary, all of the thresholds were symmetrical (i.e., improvement and decline magnitudes were equivalent). For the 80 clinical encounters when a PCP reported a clinically significant change, half (n=40) were coupled with a change in medication. Of these, most often (n=37) the PCP stated that there had been a decline in the participant's COPD. Few linked PCP encounters with clinically significant changes resulted in ordering laboratory tests or procedures (n=16) or referral to a specialist (n=5), but nearly all of the patients requiring these changes in care had a PCP-rated decline in their condition. Table 4 reports the mean thresholds, respectively, for the change scores (time 2-time 1) of the patients classified into each cell of Table 3 . With few exceptions, the CRQ measures were able to detect small changes at levels reported by the patients and their PCPs. This is evidenced by the patientperceived small decline thresholds being 1-2 points (equivalent to 1 or 2 state changes), and the optimal small improvement thresholds for both patients and PCPs being 1-5 points. An exception involves the CRQ mastery dimension and small improvements rated by PCPs, and there is prior corroboration that longitudinal validity is problematic for this domain. Patient-perceived moderate and large improvements and declines also seem credible, again with the exception of the mastery domain. The PCP-perceived average change scores for those with clinically significant declines do not display trends seen in the patient-perceived results, and PCP-related moderate improvement thresholds for dyspnea and mastery are somewhat uninterruptible given the no change and small improvement results.
In contrast, the SF-36 results are more problematic because small changes rated by patients or their PCPs yielded average change thresholds that were generally smaller than one state change value (which range from 5 to 12.5, see Table 1 ) for the SF-36 scales. It is counterintuitive to recommend that an important change has happened when a threshold is at a level less than the resulting scale scores change that occurs when an individual shifts to an adjacent response category on only one item in a scale. 12, 14 Our SF-36 results demonstrate that among the small improvement and decline thresholds, only the patient-perceived changes in mental health (small decline) and role physical (small improvement), and the PCP-classified changes for physical functioning, role physical, and general health (small improvement) meet this "at least one state change" criterion. Although some moderate and large change category thresholds do meet the state change criterion, many do not and it is difficult to interpret trends in many of the SF-36 scale results.
DISCUSSION
The results of our triangulation investigation provide several "off the shelf" CIDs for the CRQ domains when used to benchmark important changes in HRQoL domains in similar patient populations. In so doing, they also serve as a procedural outline for future multiple stakeholder studies to determine CIDs in other HRQoL measures and/or other patient populations, as well as an insight to the complications that occur when (4) 198 (7) 313 (11) 1,807 (63) 212 (7) 162 (6) 68 (2) 3 (1) 23 (6) 28 (7) 311 (80) 15 (4) 8 (2) 0 (0) Emotional 70 (2) 133 (5) 208 (7) 1,850 (64) 266 (9) 240 (8) 115 (4) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0) Fatigue 93 (3) 171 (6) 349 (12) 1,867 (65) 197 (7) 152 (5) 54 (2) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0) Mastery 52 (2) 82 (3) 158 (5) 2,053 (71) 247 (9) 196 (7) 96 (3) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0)
SF-36 Physical functioning
109 (4) 216 (8) 242 (8) 1,944 (68) 188 (7) 132 (5) 49 (2) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0)
Role physical 111 (4) 190 (7) 284 (10) 2,007 (70) 139 (5) 110 (4) 42 (1) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0)
Bodily pain 135 (5) 274 (10) 314 (11) 1,790 (62) 144 (5) 146 (5) 75 (3) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0)
General health 112 (4) 214 (7) 406 (14) 1,698 (59) 218 (8) 154 (5) 70 (2) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0) Vitality 113 (4) 219 (8) 368 (13) 1,778 (62) 199 (7) 150 (5) 57 (2) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0)
Social functioning 115 (4) 152 (5) 200 (7) 2,110 (74) 122 (4) 117 (4) 46 (2) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0)
Role emotional 70 (2) 133 (5) 208 (7) 2,132 (74) 150 (5) 126 (4) 59 (2) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0)
Mental health 64 (2) 118 (4) 195 (7) 2,031 (71) 181 (6) 185 (6) 98 (3) 3 (1) 23 (6) 30 (7) 330 (80) 15 (4) 9 (2) 0 (0) three streams of data to not converge. Beyond these products, our results also demonstrate 2 previously documented HRQoL measurement issues: (1) the merits of disease-specific measures for monitoring individual HRQoL change; 24, 25 and (2) the gap between expert panelists, patients, and their PCPs' perceptions of change 26, 27 in individual patients.
Replicating our findings in COPD populations that differ from our sample is important to determine the generalizability of our CID results to this disease group. Our expert panel's results matched the 1989 CHQ/CRQ clinical consensus panel recommendations. 5 Our patient-perceived thresholds are similar, and in some domains, a bit lower than those ascertained by Jaeschke and colleagues' pioneering HRQoL interpretation study. 5 Despite our substantial sample size (n=610 at baseline), there was a limited number of PCP-reported improvements (n= 24) or declines (n=56) in HRQoL among these outpatients over a year of enrollment, with no PCP reporting a large improvement. The scarcity of change scores available for the PCPclassified CID estimates not only questions their stability, but also underscores the need for very large (if not prohibitive) sample sizes to observe a substantial number of improvements or declines within small time intervals. In addition, there was poor agreement between the patient and PCP assessments of change, especially in these problematic cells.
These results provide investigators with benchmarks for evaluating patient-reported changes in HRQoL using these measures with COPD patients. Hence, they are a valuable resource for future interventions with primary and secondary HRQoL outcomes, demonstrating not just a statistically significant difference but also a clinically significant difference in patient change, which is currently recommended by the FDA for patient-reported outcome measures. Nonetheless, there are important limitations to these results. First, because of busy clinic schedules, we did not ask PCPs to rate their perceived changes in each HRQoL domain and scale at all linked patient encounters; instead, we asked PCPs to evaluate whether the participant had a clinically significant change in their COPD. Therefore, it is possible that patients and PCPs were rating different constructs. Yet, even the most COPD-related CRQ dyspnea domain, which assessed change in activities affected by shortness of breath, yielded a dismal weighted kappa value (κ=.29) when compared to the PCPs' COPD change rating among linked patients. The poor agreement in statistics are numerically affected by the overwhelming number of patients in the "no change" category, but nonetheless demonstrate a need for increased dialogue between patients and physicians regarding when important changes occur.
We hoped that our PCP ratings of clinically significant changes in COPD would also be documented through changes in care. Of the 80 encounters where PCPs did note a change, 47 of these were associated with a positive response to at least one change in care item. Moreover, most of the patients who had a clinically significant PCP change rating but no reported change in care action were rated as improved. Although we recognize instances where an important change in condition may not require a change in care, we encourage other researchers interested in documenting clinicians' assessments of change to also explore treatment responses to these evaluations. 28 Another limitation in this field of inquiry is the retrospective global change assessments that anchor the patients' change classifications. Several studies have demonstrated that patients have great difficulty in accurately remembering their prior health state (time 1) and then comparing it to their current health (time 2). [29] [30] [31] As a result, the change assessments are often highly correlated with current health, and uncorrelated with the time 1 assessment. To assist with this recall, we employed the use of memory markers to potentially improve the accuracy of the anchor-based methodology. Nonetheless, the use of these single-item global assessments to classify change in a domain measured through multiple items at each time point may be intuitively flawed, despite the fact that it does reflect the patient's overall perceptions of HRQoL changes. This ambiguity deserves further investigation that may necessitate improved patient-reported anchors. In addition, there is a potential problem of response shift 32 from changes in patients or PCPs understanding of conceptualization of (1) the domain or scale being assessed over their enrollment span; or (2) the response options used with the HRQoL instruments, the TRIs, or the PCP assessments. Our findings have implications for clinical research, as suggested by the FDA's call for community consensus, and for clinical practice. In these data, patients tend to report smaller changes as more clinically meaningful than do physicians. Conversely, physicians may look for changes of a magnitude that warrant clinical actions or show unquestionable improvements. The demonstrated disconnection between these two perspectives in achieving agreement regarding who has changed and the level of important change is needed. Integrating both patient and physician perspectives is important to improve research applications and interpretation of these important outcomes, 33 and patient-physician communications regarding health status, treatment options, and shared decision making for living with chronic disease like COPD.
